In this webinar, Eric Brown, MD, FACS; Erica Giblin, MD; James V. Pellicane, MD; Troy Bremer, PhD; and Leona Hamrick, DHSc, PA-C, MSL-BC, discuss how DCISionRT and its newly integrated Residual Risk Subtype (RRt) played a significant role in treatment decision making in DCIS patients identified in the RRt category. These key opinion leaders discuss actual patient cases with RRt, the differentiating factors among cases, patient preference and final treatment decisions.

In this webinar, Chirag Shah, MD; Fleure Gallant, MD; Lonika Majithia, MD; Leona Hamrick, DHSc, PA-C, MSL-BC; and Troy Bremer, PhD, discuss how DCISionRT and its newly integrated Residual Risk Subtype (RRt) played a significant role in treatment decision making in DCIS patients identified in the RRt category.

In this webinar, Dr. Pat Whitworth, MD, FACS, Chirag Shah, MD, and Troy Bremer, PhD, provide an overview of recently published data in the Red Journal of PreludeDx’s #DCISionRT and its newly integrated Residual Risk Subtype (RRt).

“As a practicing radiation oncologist, conversations with my ductal carcinoma in situ (DCIS) patients pre-DCISionRT® were always, ‘you are in a grey zone’. I just didn’t have a test that would give me a definite answer as to which patient would benefit from radiation therapy.”

How to prepare for a consultation for your breast cancer with a radiation oncologist

Life following a breast cancer diagnosis of any kind can quickly become a whirlwind of doctors appointments and consults in what feels like a million different specialties. Since we know that informed patients are often the most satisfied patients, […]

So, you or a loved one has been diagnosed with breast cancer… now what?

First and foremost, we are so terribly sorry you ever had to hear those words. Whether the diagnosis is yours or it’s a parent, child, friend or family member’s, it’s a scary time for everyone involved.

Education is arguably the most important tool with […]

We are pleased to announce that DCISionRT® has been selected as the Best Breast Cancer Precision Treatment Solution by Global Health & Pharma (GHP).

Each year, CURE® recognizes the tireless work of oncology nurses across the country who go above and beyond the call of duty to make a difference in their patients’ lives. Now more so than ever before, these oncology nurses are risking their lives with relentless dedication to care for their patients during the COVID-19 pandemic.

The Finest […]